Ultragenyx Pharmaceutical Inc. revenue by segment RARE

Annual Quarterly

Ultragenyx Pharmaceutical Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Product at $105.0 million, 61% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	730	173	214	136	207	160	167	139	165
Product	408 +20.5% share 55.9%	105 +10.5% share 60.7%	112 +38.3% share 52.3%	89 -2.2% share 65.4%	102 +41.5% share 49.1%	95 share 59.4%	81 share 48.5%	91 share 65.5%	72 share 43.7%
Royalty	322 +10.2% share 44.1%	68 +4.6% share 39.3%	102 +18.6% share 47.7%	47 -2.1% share 34.6%	106 +13.5% share 51.0%	65 share 40.6%	86 share 51.5%	48 share 34.5%	93 share 56.5%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: RARE (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Novato, CA
SEC filer status: Large accelerated filer
SEC CIK: 1515673

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.